Steven O'Reilly

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 17

Top Venues

Cellular & molecular immunology

Journal of molecular medicine (Berlin, Germany)

Annals of the rheumatic diseases

Experimental dermatology

Northumbria University

University of Liverpool (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Northumbria University

United Kingdom

Lecturer Immunology

Education History

University of Liverpool

United Kingdom

PHD :: Ageing and Chronic Disease

University of Liverpool

United Kingdom

MSC :: Immunology

Publications

Steven O'Reilly
Emerging therapeutic targets in systemic sclerosis. Journal of molecular medicine (Berlin, Germany) 102 (4) (2024)
Steven O'Reilly
Targeting pro-fibrotic macrophages with bioactive self-assembly peptides to retard kidney fibrosis - know thyself. Cellular & molecular immunology (2024)
Steven O'Reilly
Targeting pro-fibrotic macrophages with bioactive self-assembly peptides to retard kidney fibrosis - know thyself. Cellular & molecular immunology 21 (8) (2024)
Steven O'Reilly
Emerging therapeutic targets in systemic sclerosis. Journal of molecular medicine (Berlin, Germany) 102 (4) (2024)
Steven O'Reilly
Emerging therapeutic targets in systemic sclerosis. Journal of molecular medicine (Berlin, Germany) 102 (4) (2024)
Steven O'Reilly
Targeting pro-fibrotic macrophages with bioactive self-assembly peptides to retard kidney fibrosis - know thyself. Cellular & molecular immunology 21 (8) (2024)
Steven O'Reilly
Targeting pro-fibrotic macrophages with bioactive self-assembly peptides to retard kidney fibrosis - know thyself. Cellular & molecular immunology 21 (8) (2024)
Steven O'Reilly
Emerging therapeutic targets in systemic sclerosis. Journal of molecular medicine (Berlin, Germany) (2024)
Steven O'Reilly
At the crossroads of inflammation and fibrosis: epiregulin. Annals of the rheumatic diseases (2023)
Steven O'Reilly
Circulating Gremlin-1 is elevated in systemic sclerosis patients. Journal of scleroderma and related disorders 6 (3) (2021)
Steven O'Reilly
Serum amyloid A as a universal biomarker in lung disease. Internal medicine journal 51 (7) (2021)
Eleonora Adami, Sivakumar Viswanathan, Anissa A Widjaja, Benjamin Ng, Sonia Chothani, Nevin Zhihao, Jessie Tan, Pei Min Lio, Benjamin L George, Umut Altunoglu, Kakaly Ghosh, Bhairav S Paleja, Sebastian Schafer, Bruno Reversade, Salvatore Albani, Andrea Low Hsiu Ling, Steven O'Reilly, Stuart Alexander Cook
IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFβ-mediated activation of dermal fibroblasts. Rheumatology (Oxford, England) 60 (12) (2021)
Steven O'Reilly
Gremlin: a complex molecule regulating wound healing and fibrosis. Cellular and molecular life sciences : CMLS 78 (24) (2021)
John Henderson, Stefan Pryzborski, Richard Stratton, Steven O'Reilly
Wnt antagonist DKK-1 levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33a-3p. Experimental dermatology 30 (1) (2020)
Monique Hinchcliff, Steven O'Reilly
Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope. Current rheumatology reports 22 (8) (2020)
John Henderson, Laura Duffy, Richard Stratton, Dianne Ford, Steven O'Reilly
Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis. Journal of cellular and molecular medicine 24 (23) (2020)
Steven O'Reilly
Epigenetic regulation of RUNX3 in systemic sclerosis pathogenesis: time to target? Annals of the rheumatic diseases 78 (9) (2019)

Steven O'Reilly.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Steven O'Reilly